Cerebrospinal fluid sTREM2 and PGRN in the early diagnosis and progression monitoring of Alzheimer's disease: A longitudinal study
Journal of Alzheimer’s Disease · 18.11.2026
DOI: 10.1177/13872877261507326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 18.11.2026. Verfasst von Xifen Gong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Die Arbeit nennt 51 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer's disease (AD) features amyloid-β (Aβ) deposition and tau pathology, with microglial dysfunction and neuroinflammation increasingly implicated. Soluble triggering receptor expressed on myeloid cells-2 (sTREM2) and progranulin (PGRN) regulate microglial function and lysosomal homeostasis, but their dynamics across the AD continuum remain unclear.
Objective
To investigate cerebrospinal fluid (CSF) sTREM2 and PGRN in the early diagnosis and progression monitoring of AD, and their associations with Aβ pathology and other biomarkers.
Methods
Data were from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Based on CSF Aβ 42 and Clinical Dementia Rating (CDR) scores, subjects were categorized into Aβ−CN (n = 196), Aβ+CN (n = 101), Aβ+MCI (n = 378), and Aβ+AD (n = 96). Baseline demographics, neuropsychological assessments, imaging indices, and CSF biomarkers were compared. Spearman correlation, ROC curve analysis, and linear mixed-effects models (n = 255) were used.
Results
Baseline CSF sTREM2 was lower in Aβ+CN than Aβ−CN. PGRN was lower in Aβ+CN and Aβ+MCI than Aβ−CN. Over 2 years, sTREM2 increased most in Aβ+MCI and moderately in Aβ+CN, while PGRN declined in Aβ−CN, Aβ+MCI, and Aβ+AD. Both biomarkers correlated with CSF tau and p-tau in Aβ+ individuals.
Conclusions
Baseline CSF sTREM2 and PGRN have limited cross-sectional diagnostic value for AD. However, their longitudinal trajectories raise the possibility that they may reflect the microglia-lysosome axis. Combined biomarker strategies and multi-targeted therapeutic interventions warrant further investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Geriatric Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Xifen Gong, Muhammad Uzair Khalid, Jinyun Long, Ziqi Zhou, Jiayu Li, Kemeng Bai, Xiaofeng Li
Zitieren
APA
Gong, X., Khalid, M. U., Long, J., Zhou, Z., Li, J., Bai, K., Li, X., & Alzheimer’s Disease Neuroimaging Initiative (2026). Cerebrospinal fluid sTREM2 and PGRN in the early diagnosis and progression monitoring of Alzheimer's disease: A longitudinal study. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261507326
Vancouver
Gong X, Khalid MU, Long J, Zhou Z, Li J, Bai K, et al. Cerebrospinal fluid sTREM2 and PGRN in the early diagnosis and progression monitoring of Alzheimer's disease: A longitudinal study. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261507326
BibTeX
@article{Gong2026,
author = {Gong, Xifen and Khalid, Muhammad Uzair and Long, Jinyun and Zhou, Ziqi and Li, Jiayu and Bai, Kemeng and Li, Xiaofeng and Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Neuroimaging Initiative},
title = {Cerebrospinal fluid sTREM2 and PGRN in the early diagnosis and progression monitoring of Alzheimer's disease: A longitudinal study},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261507326}
}
EUVIMED